Segall Bryant & Hamill LLC Has $7.09 Million Stake in AngioDynamics, Inc. (NASDAQ:ANGO)

Segall Bryant & Hamill LLC grew its holdings in AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) by 142.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 911,443 shares of the medical instruments supplier's stock after purchasing an additional 535,958 shares during the period. Segall Bryant & Hamill LLC owned about 2.24% of AngioDynamics worth $7,091,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Quarry LP increased its holdings in shares of AngioDynamics by 75.1% in the 2nd quarter. Quarry LP now owns 6,047 shares of the medical instruments supplier's stock valued at $37,000 after purchasing an additional 2,594 shares during the period. CWM LLC increased its holdings in AngioDynamics by 981.3% in the third quarter. CWM LLC now owns 9,732 shares of the medical instruments supplier's stock worth $76,000 after buying an additional 8,832 shares during the last quarter. Mackenzie Financial Corp acquired a new position in AngioDynamics in the second quarter worth approximately $80,000. Wealth Enhancement Advisory Services LLC acquired a new position in AngioDynamics in the third quarter worth approximately $86,000. Finally, AE Wealth Management LLC acquired a new position in AngioDynamics in the second quarter worth approximately $87,000. Institutional investors and hedge funds own 89.43% of the company's stock.

Insider Activity

In other AngioDynamics news, CEO James C. Clemmer acquired 20,000 shares of AngioDynamics stock in a transaction dated Monday, October 7th. The stock was bought at an average cost of $6.03 per share, with a total value of $120,600.00. Following the completion of the transaction, the chief executive officer now owns 681,582 shares of the company's stock, valued at $4,109,939.46. The trade was a 3.02 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last three months, insiders acquired 22,568 shares of company stock valued at $135,847. 5.40% of the stock is owned by company insiders.

AngioDynamics Trading Down 1.7 %

AngioDynamics stock traded down $0.12 during trading hours on Friday, reaching $6.83. 389,609 shares of the company were exchanged, compared to its average volume of 525,791. The firm has a market cap of $277.50 million, a price-to-earnings ratio of -1.14 and a beta of 0.67. The stock has a 50-day moving average of $6.96 and a 200 day moving average of $6.78. AngioDynamics, Inc. has a 12 month low of $5.26 and a 12 month high of $8.25.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last announced its earnings results on Thursday, October 3rd. The medical instruments supplier reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.15) by $0.04. AngioDynamics had a negative return on equity of 5.86% and a negative net margin of 83.95%. The firm had revenue of $67.50 million during the quarter, compared to analysts' expectations of $67.93 million. During the same quarter in the prior year, the business earned ($0.12) earnings per share. The company's revenue was down 14.2% on a year-over-year basis. As a group, research analysts forecast that AngioDynamics, Inc. will post -0.41 EPS for the current year.

Wall Street Analyst Weigh In

ANGO has been the topic of a number of research reports. HC Wainwright restated a "buy" rating and issued a $14.00 price objective on shares of AngioDynamics in a report on Friday, October 4th. Canaccord Genuity Group dropped their price objective on AngioDynamics from $13.00 to $12.00 and set a "buy" rating on the stock in a report on Friday, October 4th.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.